Phacilitate

  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Back
  • About Us
    • Advisory Board
  • Insights and Resources
        • All Insights and Resources
          The latest and greatest Insights Phacilitate has to offer, across all our key sectors and mediums

        • Webinar Library
          View upcoming and past webinars about world of advanced therapies

           

          The Phacilitate Podcast
          Insightful conversations with industry leaders

        • Content Services
          We create game-changing content that empowers the advanced therapies industry

          • Industry Insights
            • Clinical Trials
            • Collaborations, Mergers and Acquisitions
            • Finance and Investment
            • GMP
            • Patient Access and Engagement
            • Regulatory and Standards
            • Reimbursement
            • Strategy
          • Manufacturing
            • Automation and Digitisation
            • Characterisation
            • CMC
            • GMP
            • Logistics
            • Partnering
            • Point of Care
            • Raw Materials
            • Scaling Up
            • Skills, Talent and Development
            • Supply Chain
          • Techniques
            • Allogeneic
            • Autologous
            • CAR-X
            • Cell Therapy
            • Gene Editing
            • Gene Therapy
            • NKx
            • Stem Cells
            • Viral/Non-viral Vectors
  • Latest News
  • Events
  • The Directory
    • The Cell and Gene Directory
    • Manufacturing Capacity Map
  • Membership
    • Phacilitate Network
    • Women in Advanced Therapies
Join Today
Sign In
Sign In
Join Today

Lentiviral Vector Manufacture and Testing: Challenges and Solutions

Banner
Dr Katie Roberts
22 September 2022
SHARE NOW
CAR-X
Cell Therapy
Cell-Based IO
Viral/Non-Viral Vectors
This article explores the challenges associated with lentiviral manufacture and testing, from logistical to technical scientific obstacles, and discusses potential solutions. Click here to download the full article as a PDF. 

Like all retroviruses, lentiviruses can integrate into a host genome by converting their single stranded RNA genome into double-stranded DNA. However, unlike other retroviruses, lentiviruses can transduce nondividing and quiescent cells, which make lentiviral vectors a popular choice for gene transfer within cell therapy.

Specifically, lentiviral vectors are often used for the development of ex vivo cell therapies including chimeric antigen receptor (CAR-T) cell therapies, where they represent a useful tool for gene delivery [1]. This is at least in part because introducing lentiviral vectors to cells outside the body reduces the risk of insertional mutagenesis in off-target populations and improves targeting compared with in vivo use.

Enjoying this article? Download the full eBook, here >>

Introduction to Lentiviral Vectors

Lentiviral vectors encode the necessary components to deliver gene transfer to cells and are usually constructed from plasmids. Approaches for building lentiviral vectors have changed over time, with third-generation vectors that contain only a fraction of the original viral genes considered safer than previous iterations. Third-generation lentiviral packaging systems comprise four plasmids, and some systems have been further modified, for example OXGENE’s lentiviral packaging plasmids have been engineered to improve packaging efficiency, transgene expression and overall viral yield. In addition to the evolving approaches for building lentiviral vectors, manufacturing processes and testing requirements also change over time.

THIS ARTICLE CONTINUES IN THE FULL EBOOK. DOWNLOAD IT HERE >>

 


This article has been produced in partnership with WuXi Advanced Therapies. 

More like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023

The Cell & Gene Therapy Manufacturing Capacity Map

The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023

Discover more like this

Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment

Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux

The Cell & Gene Therapy Manufacturing Capacity Map

Broken String Bioscience Closes $15M Series A Funding Round

FDA Delays the Review of Iovance’s BLA Treatment of Advanced Melanoma

logo_footer
logo_mobile_footer
Company
  • About Us
  • Events
  • Contact Us
Resources
  • Insights and Resources
  • Latest News
  • Phacilitate Podcast
  • Content Services
Network
  • Sign In
  • Join Today
social_icon Linkedin
social_icon Twitter

Clarion Events Limited is registered in England and Wales, Company Number 00454826, VAT No. GB 843845601 Registered Office: Bedford House, 69-79 Fulham High Street, London, SW6 3JW, United Kingdom.

  • Privacy Policy
  • Code of Conduct
  • Terms & Conditions
  • Cookies
Phacilitate is a part of Clarion Events Limited. © Phacilitate 2022